Clinical trials: Fungal Infections
Bacillus Anthracis (Anthrax) Infection
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults.
- Trial name
- NCT01263691
- Testing
- BioThrax, AV7909 Formulation 1, AV7909 Formulation 2
- Where
- 3 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Tinea Pedis
BE Study of Naftifine HCL
The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details.
- Trial name
- NCT02633813
- Testing
- Naftifine hydrochloride 2%, Naftin® 2% (Naftifine hydrochloride 2%)
- Where
- 14 sites in United States, Dominican Republic
- Volunteers
- 693 people
- Sponsor
- Genzum Life Sciences
Typhoid Fever
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
The purpose of this study is to evaluate the immunogenicity and the kinetics of the anti-Vi antibody response following secondary vaccination with the Novartis Vaccines Institute for Global Health (NVGH) Vi-CRM197 vaccine in…
- Trial name
- NCT01438996
- Testing
- NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Novartis
Vaginosis, Bacterial, Candidiasis, Vulvovaginal
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
This is a study to compare the safety and efficacy of the use of a intravaginal ovule containing a combination of Ketoconazole and Clindamycin to the use of an intravaginal cream containing a combination Tetracycline and…
- Trial name
- NCT01293643
- Testing
- 100 mg clindamycin /800 mg ketoconazole vaginal ovule, 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Moderate Hepatic Impairment
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
The purpose of this study is to assess the pharmacokinetics (what the body does to the medication), safety and tolerability of TMC207 and its N-monodesmethyl metabolite (M2) in healthy participants and in patients with moderate…
- Trial name
- NCT01012284
- Testing
- TMC207
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Gram-Negative Bacterial Infections
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
The primary purpose of this study is to understand the pharmacokinetics (PK) of single and multiple doses of cefiderocol in children from birth to less than 3 months of age with suspected or confirmed aerobic Gram-negative…
- Trial name
- NCT06086626
- Testing
- Cefiderocol, Standard of Care
- Where
- 4 sites in United States, South Africa and 1 more
- Volunteers
- 30 people
- Sponsor
- Shionogi
Meningococcal Infection
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
- Trial name
- NCT00310635
- Testing
- Meningococcal C conjugate vaccine
- Where
- Germany
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Novartis
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in…
- Trial name
- NCT06524414
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
- Where
- 67 sites in United States, Puerto Rico
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Pfizer
Detection Accuracy, Patient Compliance
Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients
The main purpose of this exploratory trial is to evaluate the reliability, safety and usability of the Transplantation Sensor System when the Ingestible Event Marker (IEM) is given in combination with ECMPS 360 mg tablets in…
- Trial name
- NCT01320358
- Testing
- ECMPS-IEM
- Where
- 5 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Diphtheria
A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
The purpose of this study is to assess the safety of RefortrixTM (Tdap) when administered during pregnancy in a maternal immunization program in Brazil.
- Trial name
- NCT02757950
- Testing
- Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]
- Where
- Brazil
- Volunteers
- 2,462 people
- Sponsor
- GlaxoSmithKline
Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
This study assesses the pharmacokinetics and safety of the new antifungal F901318 in AML patients.
- Trial name
- SAFEGUARD (NCT02856178)
- Testing
- F901318, Caspofungin
- Sponsor
- F2G Ltd
Fungal Infection, Acute Myelogenous Leukemia
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
The purpose of this study is: to explore the potential for different dosing strategies of posaconazole oral suspension (POS) to increase plasma levels and to profile the pharmacokinetics of these dosing strategies in patients…
- Conditions
- Fungal Infection, Acute Myelogenous Leukemia, Neutropenia
- Trial name
- NCT00686543
- Testing
- Posaconazole
- Volunteers
- 75 people
- Sponsor
- Merck Sharp & Dohme LLC
Hidradenitis Suppurativa, Atopic Dermatitis
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort.
- Trial name
- NCT06524635
- Testing
- Lutikizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
Pneumococcal Infection
A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults
phase-1 study pneumococcal conjugate vaccine study in healthy adults
- Trial name
- NCT03549208
- Testing
- LBVE01, LBVE02, Prevnar13
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LG Chem
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent…
- Trial name
- STOP-HS LTE (NCT06212999)
- Testing
- Povorcitinib
- Where
- 165 sites in United States, Australia and 15 more
- Volunteers
- 617 people
- Sponsor
- Incyte Corporation
Pseudomonas Aeruginosa Infection
Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43
This is a confirmatory, randomized, placebo-controlled, multi-center, double-blinded phase II/III study. The study population consists of male or female intensive care unit (ICU) patients with a need for mechanical ventilation…
- Trial name
- NCT01563263
- Testing
- IC43
- Where
- 50 sites in Austria, Belgium and 4 more
- Volunteers
- 803 people
- Sponsor
- Valneva Austria GmbH
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by…
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
- Trial name
- NCT02814916
- Testing
- Dalbavancin, Vancomycin, Oxacillin
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 199 people
- Sponsor
- AbbVie
Clostridium Difficile Infection
Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients
The study aims to describe the characteristics and the methods of management and follow-up of patients treated with fidaxomicin for Clostridium difficile infection (CDI).
- Trial name
- DAFNE (NCT02214771)
- Testing
- Fidaxomicin, Treatment for CDI other than fidaxomicin Type
- Where
- 24 sites in France
- Volunteers
- 296 people
- Sponsor
- Astellas Pharma S.A.S.
Skin and Subcutaneous Tissue Bacterial Infections
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
This study was designed to evaluate the efficacy of delafloxacin patients with acute bacterial skin and soft tissue infections (ABSSSI).
- Trial name
- NCT01811732
- Testing
- Delafloxacin, Vancomycin, Aztreonam
- Where
- 50 sites in United States, Croatia and 5 more
- Volunteers
- 660 people
- Sponsor
- Melinta Therapeutics, Inc.
Onychomycosis of Toenail
Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis
This study is being conducted to determine the pharmacokinetics, systemic exposure, safety and tolerability after daily topical application of SKX-16 (Luliconazole 10% Solution) for duration of 29 days in a maximal use setting in…
- Trial name
- NCT05110638
- Testing
- SKX-16 (Luliconazole 10% Solution)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- SATO Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.